C. Wang

683 total citations · 1 hit paper
15 papers, 536 citations indexed

About

C. Wang is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, C. Wang has authored 15 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 8 papers in Hematology and 5 papers in Immunology. Recurrent topics in C. Wang's work include Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Spondyloarthritis Studies and Treatments (5 papers). C. Wang is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (11 papers), Autoimmune and Inflammatory Disorders Research (8 papers) and Spondyloarthritis Studies and Treatments (5 papers). C. Wang collaborates with scholars based in United States, Canada and United Kingdom. C. Wang's co-authors include Melinda Gooderham, Lotus Mallbris, Jocelyne Papacharalambous, Vivek S. Purohit, Yves Poulin, Carla Mamolo, Maitreyi Raman, Robert Bissonnette, W.C. Ports and Kim Papp and has published in prestigious journals such as Annals of the Rheumatic Diseases, American Journal of Transplantation and British Journal of Dermatology.

In The Last Decade

C. Wang

15 papers receiving 526 citations

Hit Papers

Topical tofacitinib for atopic dermatitis: a phase II a r... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
    2016 320 citations Robert Bissonnette, Kim Papp et al. British Journal of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C. Wang United States 6 269 184 183 145 92 15 536
Alexander Marsland United Kingdom 15 238 0.9× 54 0.3× 389 2.1× 293 2.0× 35 0.4× 29 648
Anna Peroni Italy 12 249 0.9× 58 0.3× 160 0.9× 80 0.6× 85 0.9× 16 501
Faisal A. Khokhar United States 14 389 1.4× 387 2.1× 148 0.8× 109 0.8× 60 0.7× 30 717
Michael Tarzi United Kingdom 12 78 0.3× 201 1.1× 80 0.4× 197 1.4× 32 0.3× 17 563
Jatin Patel United Kingdom 12 33 0.1× 18 0.1× 150 0.8× 131 0.9× 47 0.5× 19 362
M. Vogelbruch Germany 7 165 0.6× 75 0.4× 46 0.3× 76 0.5× 99 1.1× 10 381
Marlot van der Wal Netherlands 10 87 0.3× 52 0.3× 61 0.3× 224 1.5× 43 0.5× 15 384
L. D’Auria Italy 17 138 0.5× 36 0.2× 348 1.9× 231 1.6× 52 0.6× 33 704
Marianne Tawa United States 7 356 1.3× 15 0.1× 24 0.1× 348 2.4× 127 1.4× 17 588
Masaya Yokota Japan 11 37 0.1× 62 0.3× 59 0.3× 200 1.4× 72 0.8× 23 424

Countries citing papers authored by C. Wang

Since Specialization
Citations

This map shows the geographic impact of C. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Wang more than expected).

Fields of papers citing papers by C. Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Wang. The network helps show where C. Wang may publish in the future.

Co-authorship network of co-authors of C. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of C. Wang. A scholar is included among the top collaborators of C. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Wang. C. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Charles‐Schoeman, Christina, Maya H Buch, Deepak L. Bhatt, et al.. (2022). POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE. Annals of the Rheumatic Diseases. 81. 611–612. 4 indexed citations
2.
Karpouzas, George, Zoltán Szekanecz, Eva Baecklund, et al.. (2022). POS0519 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE. Annals of the Rheumatic Diseases. 81. 517–518. 10 indexed citations
3.
Navarro‐Compán, Victoria, James Cheng‐Chung Wei, Filip Van den Bosch, et al.. (2021). POS0895 EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 3 TRIAL. Annals of the Rheumatic Diseases. 80(Suppl 1). 704.1–704. 1 indexed citations
4.
5.
Mease, Philip J., Joel M. Kremer, Stanley Cohen, et al.. (2018). SAT0243 Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programmes. Annals of the Rheumatic Diseases. 77. 983–983. 7 indexed citations
6.
7.
8.
Ritchlin, Christopher T., Jon T. Giles, Alexis Ogdie, et al.. (2018). SAT0317 Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies. Annals of the Rheumatic Diseases. 77. 1023–1023. 2 indexed citations
9.
Gladman, Dafna D., Christina Charles‐Schoeman, Iain B. McInnes, et al.. (2018). THU0299 An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies. Annals of the Rheumatic Diseases. 77. 368–368. 1 indexed citations
10.
Burmester, Gerd R, William F. C. Rigby, Ernest Choy, et al.. (2018). SAT0330 Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis. Annals of the Rheumatic Diseases. 77. 1030–1030. 3 indexed citations
11.
Kivitz, Alan, Oliver FitzGerald, Peter Nash, et al.. (2018). AB0902 Efficacy of tofacitinib by background methotrexate dose in patients with psoriatic arthritis: a post-hoc analysis of pooled data from 2 phase 3 trials. Annals of the Rheumatic Diseases. 77. 1575–1575. 2 indexed citations
12.
Ogdie, Alexis, Kurt de Vlam, Iain B. McInnes, et al.. (2018). SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Annals of the Rheumatic Diseases. 77. 971–972. 1 indexed citations
13.
Bissonnette, Robert, Kim Papp, Yves Poulin, et al.. (2016). Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. British Journal of Dermatology. 175(5). 902–911. 320 indexed citations breakdown →
14.
Busque, Stéphan, Joseph R. Leventhal, Daniel C. Brennan, et al.. (2009). Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients. American Journal of Transplantation. 9(8). 1936–1945. 114 indexed citations
15.
Weimar, Willem, Robert S. Gaston, Daniel C. Brennan, et al.. (2008). Phase 1 Dose-Escalation Study of CP-690 550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics. American Journal of Transplantation. 8(8). 1711–1718. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Marsland Breakdown of academic impact, for papers by Anna Peroni Breakdown of academic impact, for papers by Faisal A. Khokhar Breakdown of academic impact, for papers by Michael Tarzi Breakdown of academic impact, for papers by Jatin Patel Breakdown of academic impact, for papers by M. Vogelbruch Breakdown of academic impact, for papers by Marlot van der Wal Breakdown of academic impact, for papers by L. D’Auria Breakdown of academic impact, for papers by Marianne Tawa Breakdown of academic impact, for papers by Masaya Yokota
Rankless by CCL
2026